Captrust Financial Advisors Cel Sci Corp Transaction History

Captrust Financial Advisors

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$2.58 - $4.99 $784 - $1,516	-304 Reduced 7.14%	3,955 $18,000
Q2 2022 Aug 16, 2022	BUY	$2.58 - $4.99 $843 - $1,631	327 Added 8.32%	4,259 $19,000
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $15 - $30	4 Added 0.1%	3,932 $15,000
Q3 2021 Nov 16, 2021	BUY	$7.64 - $12.49 $152 - $249	20 Added 0.51%	3,928 $43,000
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $217 - $687	25 Added 0.64%	3,908 $34,000
Q1 2021 May 17, 2021	SELL	$12.0 - $27.64 $31,200 - $71,864	-2,600 Reduced 40.1%	3,883 $59,000
Q4 2020 Feb 16, 2021	SELL	$11.05 - $16.62 $21,326 - $32,076	-1,930 Reduced 22.94%	6,483 $76,000
Q3 2020 Nov 17, 2020	BUY	$11.69 - $14.54 $29,809 - $37,077	2,550 Added 43.49%	8,413 $113,000
Q2 2020 Aug 14, 2020	BUY	$9.75 - $17.6 $57,164 - $103,188	5,863 New	5,863 $84,000
Q4 2019 Feb 14, 2020	SELL	$6.71 - $9.55 $46,131 - $65,656	-6,875 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.0 - $9.6 $23,250 - $37,200	3,875 Added 129.17%	6,875 $61,000
Q2 2019 Aug 13, 2019	BUY	$3.77 - $8.67 $11,310 - $26,010	3,000 New	3,000 $25,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.